Skip to Content
You are currently on the new version of our website. Access the old version .
  • Case Report
  • Open Access

19 March 2024

21 Pages

Atlas of Tumor and Tumor Microenvironment Cells of Lymphovascular Space Invasion (LVSI) in High-Grade Serous Endometrial Adenocarcinoma: A Case Study

,
,
,
,
,
,
,
and
1
Department of Pathology, Avera Cancer Institute, Sioux Falls, SD 57108, USA
2
Translational Oncology Laboratory, Avera Cancer Institute, Sioux Falls, SD 57108, USA
3
Assistant VP Outpatient Cancer Clinics, Avera Cancer Institute, Sioux Falls, SD 57108, USA
4
Department of Gynecologic Oncology, Avera Cancer Institute, Sioux Falls, SD 57108, USA

Abstract

Lymphovascular invasion (LVSI) is defined as the presence of tumor cells within a definite endothelial-lined space (lymphatics or blood vessels) in the organ surrounding invasive carcinoma. The presence of LVI is associated with an increased risk of lymph nodes and distant metastases. Lymphovascular invasion is described as cancer within blood or lymph vessels and is an independent risk factor for metastasis, recurrence, and mortality. This study aims to present the marker-based immunohistological characterization of cells around LVSI in a high-grade adenocarcinoma of the endometrium to build a cellular atlas of cells of LVSI. A cellular characterization of the cells around lymphovascular space invasion in a 67-year-old female patient with invasive high-grade serous endometrial adenocarcinomas is presented. Resected tumor tissue from a consented patient with invasive high-grade serous endometrial adenocarcinoma was obtained within an hour of surgery. The expressions of the epithelial markers (CK8, 18, and EpCAM), LCA (leukocyte common antigen) marker (CD45), proliferation marker (Ki67), apoptosis markers (cleaved PARP and cleaved caspase3), immune cell markers (CD3, CD4, CD8, CD56, CD68, CD163, FoxP3, PD-1, PD-L1), pro-inflammatory marker (IL-12-RB2), and fibroblast/mesenchyme markers (S100A7, SMA, and TE-7) of the resected tissue on the IHC stains were evaluated and scored by a pathologist. Acknowledging the deterministic role of LVSI in a high-grade adenocarcinoma of the endometrium, our study presents the first marker-based immunohistological atlas of the tumor and TME compartments in the context of epithelial cell markers, proliferation markers, apoptosis markers, macrophage markers, and fibroblast markers. Our study demonstrates that an aggressive disease like a high-grade adenocarcinoma of the endometrium inflicts the pro-metastatic event of LVSI by involving the immune landscape of both tumor and TME. This study demonstrates, for the first time, that the tumor cells within LVSI are positive for IL-12R-B2 and S100A4.

1. Introduction

Lymphovascular space invasion (LVSI), histological grade, and myometrial invasion are important prognostic factors of endometrial carcinoma, one of the most frequent gynecological cancers in developed countries [1]. LVSI, found in up to 35% of patients with endometrial cancers [2], is pathologically defined as the detection of tumoral cells in lymphatics or small vessels outside the core tumor. LVSI is characterized by the tumor cells within endothelium-lined spaces around the primary tumor that are observed as “free-floating” cell clusters, which frequently fit the space shape.
Uterine serous carcinoma is an uncommon form of endometrial cancer [3]. Serous carcinoma is the prototype of type-II endometrial cancer and accounts for 10% of all endometrial carcinomas; although rare, they are very aggressive tumors and are regarded as high-grade [4]. Despite its rarity, uterine serous carcinoma accounts for a disproportionate number of endometrial cancer deaths (estimated at approximately 40%; see [5]). The poor clinical outcomes for patients are attributable, in part, to an increased risk for occult metastases as compared to endometrioid endometrial carcinoma (See [4]).
The significance of LVSI in uterine serous carcinoma is recognized [6]. The presence and extent of LVSI and cervical stromal invasion are reported predictors for lymph node metastasis in uterine serous carcinoma [7].
In this case study, we have built a cellular atlas of LVSI in HGS-invasive endometrial adenocarcinoma. In this effort, we have used six types of marker-based characterization of the tumor compartment and cells of the tumor microenvironment (TME), including epithelial markers, LCA (leukocyte common antigen) markers, proliferation markers, apoptosis markers, immune cell markers, and fibroblast (mesenchyme) markers.

3. Discussion

As LVSI has been recognized as one of the initial events in the lymphomatous and hematogenous metastases in endometrial carcinoma [3], LVSI is associated with lower overall survival, higher risk of recurrence, lymph node metastasis, and distant metastasis that LVSI correlates with poorer prognosis in endometrial cancers of FIGO stage I–III. The LVSI is associated with higher histologic grade and deep MMI and is considered an independent poor prognostic factor in endometrial carcinoma [10]. We observed no histomorphologic differences in the LVSI features among endometrial adenocarcinoma subtypes. Recently, LVSI in endometrial carcinoma has been known to be a prognostic factor independent of molecular signature [11]. The deep myometrial invasion correlates to positive LVSI, positive LNM, cancer recurrence, and poor OS for endometrial cancer patients [12]. Due to the high frequency of hematogenous dissemination in patients with serous carcinoma, LVSI is the primary feature of the dissemination. Here, we studied the cellular characterization of LVSI in a case of high-grade (3) and stage (IIIC2) invasive serous adenocarcinoma patients. Since we studied the LVSI, we also tested the patient’s blood for circulating tumor cells (CTCs) and circulating cancer-associated macrophage-like cells (CAMLs) on the day of the surgery. Although IHC can aid in the identification of LVSI in difficult or challenging cases, keeping in mind the histopathological features of our case, in line with other reports [13,14], we used standard H&E to aid in the diagnosis of LVSI in our case. As mentioned earlier, CTC and CAMLs were identified in our laboratory [15,16]. The patient’s blood was positive for both CTC and CAMLs.
Our study demonstrates, for the first time, that the tumor cells within LVSI were positive for IL-12R-B2 and S100A4. As an ideal example of cancer associated with epithelial–mesenchymal transition (EMT), which exhibits cancer stem cell (CSC)-like traits, uterine carcinosarcoma, more specifically, a high-grade form exhibiting LVSI, demands an in-depth understanding of the expression of EMT markers, like S100A4. S100A4 is a well-established tumor metastasis mediator in endometrial cancers, and estrogen-related receptor γ knockdown transcriptionally inhibits S100A4 expression to promote the expression of its downstream target E-cadherin, and vice versa [17]. Although S100A4 is a known inducer of EMT in uterine tumorigenesis [18], little is known about its involvement in LVSI and its differentiation. In a cell line-based study, Tochimoto et al. reported that cell lines stably overexpressing S100A4 enhanced CSC properties and decreased cell proliferation and acceleration of cell migration [19]. In their clinical samples, the S100A4 score was found to be significantly higher in sarcomatous as compared with carcinomatous components and was positively correlated with ALDH1, Slug, and vimentin scores and inversely with Ki-67-labeling indices. The study suggested the involvement of a S100A4-related signaling cascade, although initiated in the carcinomatous tumor components, to the establishment of EMT properties but can be a part of the event toward a divergent sarcomatous differentiation. The presence of LVSI indicates that the tumor is histopathologically predisposed to metastatic progression. S100A4 is known for its role in a number of cellular processes, including cell-cycle progression and metastasis. Hence, it is logical to argue that the S100A4 positivity of tumor cells in the LVSI is associated with poor prognosis. Our study demonstrates, for the first time, that the tumor cells within LVSI were positive for S100A4, highlighting its role as a promising prognostic marker in endometrial adenocarcinoma, especially in high-grade LVSI form.
The endometrial cancer (EC) cells in the LVSI in our study appeared to be positive with S100A4 IHC signal. S100A4 has been thought of as a crucial EMT mediator since the Wnt/B-catenin signaling pathway directly controls it, more specifically in the context of addressing the activation of the Wnt/B-catenin pathway in a diverse landscape of endometrial carcinogenesis [20]. Studies have reported that S100A4 promotes endometrial cancer progress through epithelial–mesenchymal transition regulation [18]. S100A4 promoted the migration and invasion capacity of EC cells via EMT modification. In their study, Hua et al. reported that an aberrant S100A4 expression may predict EC progression and play an important role in regulating EC cell invasion through EMT regulation, indicating that S100A4 is a promising therapeutic target. Although a future confirmation is warranted, it is very likely that the tumor cells are undergoing EMT.
When a tumor undergoes EMT, it is presumed that the intrinsic tumor-suppressor mechanisms have failed, and hence, it is understood that the CSCs experience extrinsic pressure from tumor-infiltrating lymphocytes (TILs) [21,22]. As various TILs interact with secreted cytokines in the tumor microenvironment and typically either kill tumors at early stages or promote tumors at advanced stages, CSCs and TILs form the “three-E” sequential cancer immunoediting phases: elimination, equilibrium, and escape [21,22,23,24]. Although intrinsic mechanisms of epigenetic immunoediting for IL-12-RB2 are not clear, IL-12-RB2 regulates both the number and functional maturity of regulatory T cells. IL-12RB2 is a part of homeostasis within the tumor cells and TILs, and this homeostasis affects prognosis [25]. Our results show that the granular cytoplasmic expression of IL-12-B2 was found in tumor cells uniformly in both regions of invasion and LVSI. However, the degree of expression was much lesser than that of the highly positive TILs. Pan-cancer data also show a limited expression of IL-12-RB2 in endometrial tumor cells as compared to other solid tumors, namely melanoma, breast, kidney, and colorectal cancers. Our data warrant further studies to understand the prognostic significance of IL-12-B2 expression in endometrial cancers.

4. Conclusions

Our case study demonstrates the characteristics of tumor cells and cells of TME around LVSI in a rare yet aggressive form of endometrial adenocarcinoma. Epithelial tumor cells of an aggressive disease enforce several pro-metastatic event(s), including LVSI, via direct and indirect crosstalk with the immune and fibroblastic/mesenchymal stromal cells of TME. This study demonstrates, for the first time, that the tumor cells within LVSI are positive for IL-12R-B2 and S100A4.

Author Contributions

R.S.: Pathologist who provided the confirmatory evaluation of IHC staining and reviewed MS. A.D.: Research Associate who obtained consent from patients and provided technical assistance in record keeping and obtained outcome data from EMR. X.L.: Research Associate Lead who standardized and performed double ICC and IHC of FFPE and CAFs. J.C.A.: Laboratory Supervisor who standardized and performed flow-cytometry for the standardization of staining. K.G.: Provided insight into the overall logistical management of the study. D.S.: Surgeon who provided clinical insight into endometrial and ovarian tumors corresponding to the blood samples. L.R.E.: Surgeon who provided clinical insight into endometrial and ovarian tumors corresponding to the blood samples. P.D.: Senior Scientist who helped in CAFs characterization and in writing the MS. N.D.: Conceptualization, supervision, project administration, data analysis, writing, and editing. All authors have read and agreed to the published version of the manuscript.

Funding

This study was funded by the Avera Cancer Institute.

Institutional Review Board Statement

Anonymized tissue samples were collected at surgery from the patient with endometrial cancer following their informed (IRB approved: Protocol Number Study: 2017.053-100399_ExVivo001 Date of approval 28 April 2022) consent.

Data Availability Statement

This study was translational/experimental in nature. No public data were used. All experimental data are presented in the figures.

Acknowledgments

We acknowledge the generous contribution of the Avera Cancer Institute for funding the entire study and being supportive to the article publication. We acknowledge the patients and their families for their participation in the ex vivo study at the Avera Cancer Institute.

Conflicts of Interest

Author Pradip De was employed by Viecure. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 2022, 72, 7–33. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  2. Tortorella, L.; Restaino, S.; Zannoni, G.F.; Vizzielli, G.; Chiantera, V.; Cappuccio, S.; Gioe, A.; La Fera, E.; Dinoi, G.; Angelico, G.; et al. Substantial lymph-vascular space invasion (LVSI) as predictor of distant relapse and poor prognosis in low-risk early-stage endometrial cancer. J. Gynecol. Oncol. 2021, 32, e11. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  3. Bogani, G.; Ray-Coquard, I.; Concin, N.; Ngoi, N.Y.L.; Morice, P.; Enomoto, T.; Takehara, K.; Denys, H.; Nout, R.A.; Lorusso, D.; et al. Uterine serous carcinoma. Gynecol. Oncol. 2021, 162, 226–234. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  4. Dewdney, S.B.; Kizer, N.T.; Andaya, A.A.; Babb, S.A.; Luo, J.; Mutch, D.G.; Schmidt, A.P.; Brinton, L.A.; Broaddus, R.R.; Ramirez, N.C.; et al. Uterine serous carcinoma: Increased familial risk for lynch-associated malignancies. Cancer Prev. Res. 2012, 5, 435–443. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  5. Moore, K.N.; Fader, A.N. Uterine papillary serous carcinoma. Clin. Obstet. Gynecol. 2011, 54, 278–291. [Google Scholar] [CrossRef] [Scilit]
  6. Winer, I.; Ahmed, Q.F.; Mert, I.; Bandyopadhyay, S.; Cote, M.; Munkarah, A.R.; Hussein, Y.; Al-Wahab, Z.; Elshaikh, M.A.; Alosh, B.; et al. Significance of lymphovascular space invasion in uterine serous carcinoma: What matters more; extent or presence? Int. J. Gynecol. Pathol. 2015, 34, 47–56. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  7. Qian, Y.; Pollom, E.L.; Nwachukwu, C.; Seiger, K.; von Eyben, R.; Folkins, A.K.; Kidd, E.A. Extent of lymphovascular space invasion may predict lymph node metastasis in uterine serous carcinoma. Gynecol. Oncol. 2017, 147, 24–29. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  8. Lavie, O.; Ben-Arie, A.; Segev, Y.; Faro, J.; Barak, F.; Haya, N.; Auslender, R.; Gemer, O. BRCA germline mutations in women with uterine serous carcinoma—Still a debate. Int. J. Gynecol. Cancer 2010, 20, 1531–1534. [Google Scholar]
  9. Sulaiman, R.; De, P.; Aske, J.C.; Lin, X.; Dale, A.; Koirala, N.; Gaster, K.; Espaillat, L.R.; Starks, D.; Dey, N. Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers. Int. J. Mol. Sci. 2023, 24, 11079. [Google Scholar] [CrossRef] [Scilit]
  10. Guntupalli, S.R.; Zighelboim, I.; Kizer, N.T.; Zhang, Q.; Powell, M.A.; Thaker, P.H.; Goodfellow, P.J.; Mutch, D.G. Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. Gynecol. Oncol. 2012, 124, 31–35. [Google Scholar] [CrossRef] [Scilit]
  11. Raffone, A.; Travaglino, A.; Raimondo, D.; Neola, D.; Maletta, M.; Santoro, A.; Insabato, L.; Casadio, P.; Fanfani, F.; Zannoni, G.F.; et al. Lymphovascular space invasion in endometrial carcinoma: A prognostic factor independent from molecular signature. Gynecol. Oncol. 2022, 165, 192–197. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  12. Wang, J.; Xu, P.; Yang, X.; Yu, Q.; Xu, X.; Zou, G.; Zhang, X. Association of Myometrial Invasion With Lymphovascular Space Invasion, Lymph Node Metastasis, Recurrence, and Overall Survival in Endometrial Cancer: A Meta-Analysis of 79 Studies With 68,870 Patients. Front. Oncol. 2021, 11, 762329. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  13. Peters, E.E.M.; Bartosch, C.; McCluggage, W.G.; Genestie, C.; Lax, S.F.; Nout, R.; Oosting, J.; Singh, N.; Smit, H.; Smit, V.; et al. Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer. Histopathology 2019, 75, 128–136. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  14. Rafiee, A.; Mohammadizadeh, F. Association of Lymphovascular Space Invasion (LVSI) with Histological Tumor Grade and Myometrial Invasion in Endometrial Carcinoma: A Review Study. Adv. Biomed. Res. 2023, 12, 159. [Google Scholar] [CrossRef] [Scilit]
  15. Sulaiman, R.; De, P.; Aske, J.C.; Lin, X.; Dale, A.; Vaselaar, E.; Ageton, C.; Gaster, K.; Espaillat, L.R.; Starks, D.; et al. Identification and Morphological Characterization of Features of Circulating Cancer-Associated Macrophage-like Cells (CAMLs) in Endometrial Cancers. Cancers 2022, 14, 4577. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  16. Sulaiman, R.; De, P.; Aske, J.C.; Lin, X.; Dale, A.; Vaselaar, E.; Koirala, N.; Ageton, C.; Gaster, K.; Plorde, J.; et al. A Laboratory-Friendly CTC Identification: Comparable Double-Immunocytochemistry with Triple-Immunofluorescence. Cancers 2022, 14, 2871. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  17. Hua, T.; Wang, X.; Chi, S.; Liu, Y.; Feng, D.; Zhao, Y.; Wang, H. Estrogen-related receptor gamma promotes the migration and metastasis of endometrial cancer cells by targeting S100A4. Oncol. Rep. 2018, 40, 823–832. [Google Scholar] [CrossRef] [Scilit]
  18. Hua, T.; Liu, S.; Xin, X.; Cai, L.; Shi, R.; Chi, S.; Feng, D.; Wang, H. S100A4 promotes endometrial cancer progress through epithelial-mesenchymal transition regulation. Oncol. Rep. 2016, 35, 3419–3426. [Google Scholar] [CrossRef] [Scilit]
  19. Tochimoto, M.; Oguri, Y.; Hashimura, M.; Konno, R.; Matsumoto, T.; Yokoi, A.; Kodera, Y.; Saegusa, M. S100A4/non-muscle myosin II signaling regulates epithelial-mesenchymal transition and stemness in uterine carcinosarcoma. Lab. Investig. 2020, 100, 682–695. [Google Scholar] [CrossRef] [Scilit]
  20. De, P.; Aske, J.C.; Dale, A.; Rojas Espaillat, L.; Starks, D.; Dey, N. Addressing activation of WNT beta-catenin pathway in diverse landscape of endometrial carcinogenesis. Am. J. Transl. Res. 2021, 13, 12168–12180. [Google Scholar] [PubMed]
  21. Dunn, G.P.; Bruce, A.T.; Ikeda, H.; Old, L.J.; Schreiber, R.D. Cancer immunoediting: From immunosurveillance to tumor escape. Nat. Immunol. 2002, 3, 991–998. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  22. Mittal, D.; Gubin, M.M.; Schreiber, R.D.; Smyth, M.J. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr. Opin. Immunol. 2014, 27, 16–25. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  23. Schreiber, R.D.; Old, L.J.; Smyth, M.J. Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion. Science 2011, 331, 1565–1570. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  24. Quezada, S.A.; Peggs, K.S.; Simpson, T.R.; Allison, J.P. Shifting the equilibrium in cancer immunoediting: From tumor tolerance to eradication. Immunol. Rev. 2011, 241, 104–118. [Google Scholar] [CrossRef] [Scilit]
  25. Tao, Y.; Tao, T.; Gross, N.; Peng, X.; Li, Y.; Huang, Z.; Liu, L.; Li, G.; Chen, X.; Yang, J. Combined Effect of IL-12Rbeta2 and IL-23R Expression on Prognosis of Patients with Laryngeal Cancer. Cell Physiol. Biochem. 2018, 50, 1041–1054. [Google Scholar] [CrossRef] [Scilit]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.